Physician profile
Brady L Cook
NPI 1467502930
$5,527.75
in general payments reported to CMS, 2019-2025
43 companies · $742 in 2025
The $742 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $501 · 2021: $771 · 2022: $1,095 · 2023: $1,067 · 2024: $749 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533 · Education: $25.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.81 |
| Education | $25.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,981.75 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $523.80 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $343.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $316.36 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.94 | 2020-2022 | |
| Mylan Specialty L.P. | $186.46 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $167.56 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $143.74 | 2019-2025 | Veozah |
| Pfizer INC. | $124.35 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $124.09 | 2019-2024 | Spravato |
| Medtronic, INC. | $123.68 | 2021-2024 | Minimed 780g, Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $115.59 | 2019-2023 | |
| Penumbra, INC. | $107.46 | 2023 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $82.58 | 2019-2025 | Airsupra, Farxiga |
| Allergan, INC. | $77.65 | 2019-2020 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $70.68 | 2021-2024 | Dexcom G6 Transmitter |
| Ge Healthcare | $59.34 | 2019-2020 | |
| Abbott Laboratories | $59.13 | 2021-2023 | Freestyle Libre 3 |
| Insulet Corporation | $54.28 | 2025 | Omnipod |
| Sunovion Pharmaceuticals INC. | $50.41 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.88 | 2019-2025 | Eliquis |
| Phathom Pharmaceuticals, INC. | $43.61 | 2024-2025 | Voquezna |
| Edwards Lifesciences Corporation | $40.91 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ultragenyx Pharmaceutical INC. | $37.77 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.39 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $33.24 | 2023-2024 | Opsumit |
| Tandem Diabetes Care, INC. | $32.66 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sumitomo Pharma America, INC. | $29.94 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $28.94 | 2022 | |
| Merck Sharp & Dohme LLC | $28.76 | 2019-2020 | |
| Corcept Therapeutics | $28.11 | 2024-2025 | Korlym |
| Kerecis Limited | $27.97 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Otsuka America Pharmaceutical, INC. | $26.77 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $22.22 | 2022 | |
| Viatris Specialty LLC | $20.10 | 2025 | Yupelri |
| Lundbeck LLC | $18.11 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $16.67 | 2025 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $16.43 | 2025 | Injectafer |
| Shield Therapeutics INC | $16.43 | 2024 | |
| Boston Scientific Corporation | $16.22 | 2025 | General - Pain Management |
| Sanofi-Aventis U.S. LLC | $15.51 | 2022 | |
| Inspire Medical Systems, INC. | $15.00 | 2023 | Inspire |
| Medtronic USA, INC. | $14.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brady Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.